The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia

Not Applicable

Recruiting

• Conditions: SCHIZOPHRENIA 1 (Disorder); Psychosocial Adaptation; Treatment Adherence

• Registration Number: NCT07144592
• Lead Sponsor: Muş Alparslan University

Brief Summary

The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.

The study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).

The experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).

Detailed Description

Objective:

Schizophrenia is a chronic psychiatric disorder that significantly affects thought, emotion, and behavior, often limiting social functioning, treatment adherence, and integration into daily life. There is an increasing need for person-centered, empowering, and brief intervention models in psychiatric nursing. This study aims to determine the effects of a solution-focused approach (SFA)-based individual intervention on psychosocial adjustment and treatment adherence in individuals with schizophrenia.

Study Design:

This research will use a pretest-posttest randomized controlled experimental design with a control group.

Study Population:

The study will include 60 individuals diagnosed with schizophrenia according to DSM-5 diagnostic criteria, considered clinically stable, and registered at a Community Mental Health Center affiliated with a university hospital in Türkiye. Participants will be randomly assigned to an experimental group (n=30) or a control group (n=30) using computer-assisted randomization.

Intervention:

Experimental Group: Participants will receive individual solution-focused therapy sessions once per week for six consecutive weeks. The sessions will emphasize individual strengths, recall positive coping experiences, support future goal setting, and provide guidance on repeating effective solutions.

Control Group: Participants will receive no additional intervention beyond usual care.

Outcome Measures:

Data will be collected with the following instruments:

Personal Information Form

Psychosocial Adjustment Scale (PSSAS)

Medication Adherence Scale (MARS)

Statistical Analyses:

Planned analyses will include independent samples t-tests, paired t-tests, and ANCOVA.

Study Timeline

• Study Start: 2025-01-01
• Primary Completion: 2025-02-25
• Status Verified: 2025-08
• Study First Submitted: 2025-08-06
• Study First Submitted QC: 2025-08-20
• Last Update Submitted: 2025-08-20
• Study First Posted: 2025-08-27
• Last Update Posted: 2025-08-27
• Study Completion: 2025-10-25

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria,

Being between 18 and 65 years of age,

Being literate and verbally communicative,

Being clinically stable (not exhibiting symptoms of acute psychosis),

Being registered with a Community Mental Health Center (CMHC) and receiving regular services,

Being cognitively competent enough to participate in individual interviews during the research process,

Being an individual currently receiving psychiatric treatment and taking medication,

Agreeing to participate voluntarily in the study and signing a written informed consent form.

Exclusion Criteria

• those who do not meet the inclusion criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
pretest (6-week solution-focused approach before the intervention)	Baseline (within 1 week before intervention)	2\. Medication Adherence (MARS); Description: Measured with the Medication Adherence Scale (MARS), which assesses adherence to prescribed pharmacological treatment. Scores range from 0 to 10; higher scores indicate better medication adherence.; Time Frame: Baseline (within 1 week before intervention); Unit of Measure: Total score (0-10)

Secondary Outcome Measures

Name	Time	Method
posttest (After the 6-week solution-focused approach intervention)	Post-intervention (6 weeks after completion of the intervention)	2\. Medication Adherence Post-Intervention (MARS); Description: Medication Adherence Scale (MARS). Scores range from 0 to 10; higher scores indicate better medication adherence.; Time Frame: Post-intervention (6 weeks after completion of the intervention); Unit of Measure: Total score (0-10)

Trial Locations

Locations (1)

Community Mental Health Center; Muş, Turkey (Türkiye)